1077HS (10779): HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Study Status Study Restriction

Closed to Follow Up

US & Non-US

What is 1077HS?

1077HS is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). 1077HS is conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but do not otherwise meet criteria to initiate HAART for their own health. The study is designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduces morbidity and mortality compared to discontinuation and re-initiation of HAART according to current standards of care.

>> Read more about PROMISE study results

Study documents:

Other Study Implementation Documents

Sites where the study is implemented:

CRS ID Site Name City Country

5082

Hospital General de Agudos Buenos Aires Argentina NICHD CRS

Buenos Aires

Argentina

12701

Gaborone Prevention/Treatment Trials CRS

Gaborone

Botswana

12702

Molepolole Prevention/Treatment Trials CRS

Molepolole

Botswana

5071

Inst of Pediatrics Fed Univ Rio de Janeiro NICHD CRS

Rio de Janeiro

Brazil

5072

Hospital dos Servidores Rio de Janeiro

Rio de Janeiro

Brazil

5073

SOM Federal University Minas Gerais Brazil

Minas Gerais

Brazil

5074

Univ of Sao Paulo Brazil

Sao Paulo

Brazil

5084

University Caxias do Sul Brazil NICHD CRS

Caxias do Sul

Brazil

5097

Hosp. Geral De Nova Iguacu Brazil NICHD CRS

Rio de Janeiro, Rio de Janeiro

Brazil

5098

Hospital Santa Casa Porto Alegre Brazil NICHD CRS

Rio Grande do Sul

Brazil

5117

Hospital Nossa Senhora da Conceicao CRS

Porto Alegre

Brazil

30022

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

Port-au-Prince

Haiti

5115

Siriraj Hospital Mahidol University CRS

Bangkok

Thailand

5116

Chiang Rai Regional Hospital CRS

Muang

Thailand

5124

Bhumibol Adulyadej Hospital

Bangkok

Thailand

31784

Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS

Chiang Mai

Thailand

3801

Texas Childrens Hosp. CRS

Houston

United States of America

4001

Chicago Children's CRS

Chicago

United States of America

4201

University of Miami Pediatric/Perinatal HIV/AIDS

Miami

United States of America

4601

UCSD Mother-Child-Adolescent HIV Program

San Diego

United States of America

5011

Boston Medical Center Pediatric HIV Program

Boston

United States of America

5013

Jacobi Medical Center Bronx

Bronx

United States of America

5017

Univ of Washington Children's Hospital Seattle

Seattle

United States of America

5031

San Juan City Hospital

San Juan

United States of America

5040

SUNY Stony Brook

Stony Brook

United States of America

5048

University of Southern California LA

Los Angeles

United States of America

5051

University of Florida Jacksonville

Jacksonville

United States of America

5052

University of Colorado Denver NICHD CRS

Aurora

United States of America

5055

South Florida CDTC Ft Lauderdale NICHD CRS

Fort Lauderdale

United States of America

5092

Johns Hopkins University, Baltimore

Baltimore

United States of America

5112

UCLA - David Geffen School of Medicine

Los Angeles

United States of America

5114

Bronx-Lebanon Hospital IMPAACT

Bronx

United States of America

6501

St. Jude/UTHSC CRS

Memphis

United States of America

6601

University of Puerto Rico Pediatric HIV/AIDS Research Program CRS

San Juan

United States of America

Study contacts:

Study Chair: Judith Currier

DAIDS Medical Officer: Devasena Gnanashanmugam

NICHD Medical Officer: Nahida Chakhtoura

Clinical Trials Specialist: Anne Coletti

Clinical Trials Specialist: Katie McCarthy

Data Manager: Barbara Heckman

Data Manager: Linda Marillo

Drug Co. Representative: Melody Billena

Drug Co. Representative: Randi Leavitt

Drug Co. Representative: James Rooney

Drug Co. Representative: Wendy Snowden

Drug Co. Representative: Navdeep Thoofer

Drug Co. Representative: Helen Watson

Field Representative: Nina Sublette

Immunologist: Adriana Weinberg

Investigator: Andrea Ciaranello

Investigator: Kenneth Freedberg

Investigator: Risa Hoffman

Laboratory Data Manager (LDM): Alexander Benns

Laboratory Data Manager (LDM): Kyle Lambert

Laboratory Data Manager (LDM): Rebecca LeBlanc

Laboratory Technologist: Amy James Loftis

Laboratory Technologist: William Kabat

Medical Monitor: Renee Browning

Medical Officer: Karin Klingman

Protocol Pharmacist: Lynette Purdue

Statistician: Paula Britto

Statistician: Sean Brummel

Statistician: David Shapiro

Virologist: Susan Fiscus

Westat Representative: Kathryn Myers

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.